Tell us about your exciting accomplishments!

OVPR staff is excited about the breakthroughs in research and scholarly accomplishments on our campus. If you have been awarded a grant, submitted a paper for publication or been notified that your research is being published in a scholarly journal, please contact us at so we can share the news with the rest of the OUHSC research community.

"The ORA submission process: A review for new investigators"
New PI Training 04-20-16 Final

Other helpful information

On this page, you will also find useful Institutional Data that you may be asked to provide when submitting a proposal.   Please let us know if there is additional information or links you would like to see on our site. Simply complete our Suggestion Form.

ORA Research News - Monday, September 21, 2020





Attached is the HSC COVID-19 Return Plan that was updated September 11, 2020

Substantive changes are summarized below:

  1. The process for addressing sanitizing needs when a COVID-19 individual has been in academic or department space has 
  2. been updated, based on the increased frequency of cleaning and updated transmission data (Section VI.B.2 of the Return Plan).
  3. Instructions for who must complete the online Screening and Reporting Tool have been streamlined (Section VIII).  

Travel, 7-day absence from campus, and attendance at events of 10 or more no longer require submission of the Tool

The Tool must be submitted in 4 instances: 

  • When you have symptoms that are consistent with COVID-19
  • When you have a positive COVID-19 test or are awaiting COVID-19 test results
  • When you have been in close contact (defined as being within 6 feet for approximately 15 minutes of someone who 

is COVID-19 positive or who is awaiting COVID-19 test results)

  • When you have a household member who has tested positive for COVID-19 in the last 14 days

The Travel (

and Visitor/Vendor (

FAQs have been updated to reflect these changes.  For example, vendors and visitors must complete the online Tool before their 

first visit to campus and after that, only if they meet the other instances, such as having COVID-19 symptoms.

  1. Travel (Section IX of the Return Plan) has been updated to reflect that University domestic and international travel are
  2. permitted if determined by the dean to be mission critical, as defined in the section.



Save the Date – ORA Noon Conference offered via Zoom

October 21, 2020 at 1:00 pm

Topic: Writing Manuscripts

Description: Communicating the results of your research is an important part of the research enterprise. This presentation will

cover how to write original articles and provide tools necessary to successfully write, submit, and publish a manuscript. It will 

introduce the purpose of each section of a research article, describe the recommended approach, and provide information about 

common mistakes in writing for biomedical publications.

Please register in advance for this meeting:

After registering, you will receive a confirmation email containing information about joining the meeting.




The OK Catalyst is part of the Tom Love Innovation Hub at the University of Oklahoma.  If you are looking for assistance on 

developing and/or funding your entrepreneurial ideas please see upcoming events sponsored by OK Catalyst at:



The University of Baltimore’s Center for Drug Policy and Prevention (CDPP) invites sub-award applications 

for the Combating Opioid Overdose Through Community-level Intervention Initiative (COOCLI) Initiative, 

funded by the Office of National Drug Control Policy (ONDCP, CFDA=95.007).

Sub-recipients must focus on opioid-involved overdoses or overdoses involving stimulants in the regions of the United States 

with the highest rates of fatal and non-fatal overdoses.  Also, they must:

  • Use evidence-based or promising approaches to implement or enhance new or on-going community-based programs

that aim to reduce opioid or other drug overdoses.

  • Once implemented, evaluate these community-based efforts to assess their efficacy in reducing overdoses and other

harms of opioid (mis)use and other substance use.

  • Support and promote collaboration between public safety and public health agencies to ensure that overdose reduction

efforts are aligned and that communities benefit from a comprehensive and coordinated response

These funds will help identify innovative solutions that move beyond traditional health and law enforcement policies. UB’s center, 

housed in the College of Public Affairs, will act as the authority for all administrative and financial aspects of the grant. 

The center encourages local government agencies, public and private universities, advocacy organizations and nonprofits 

nationwide to apply for funding.

CDPP and UB officials will begin accepting applications for subawards from the grant on October 1, 2020. Applications are

due to UB no later than midnight Eastern Standard Time, Nov. 2, 2020. Organizations that wish to apply for funding for their

opioid-related intervention effort may do so by following the instructions provided on our website:



Office of Technology Commercialization presents a new opportunity to engage with industry (click here:

for more information, or email or  Submission entails a one-page research summary 

plus any relevant non-confidential supporting documents (Deadline 10/19/20).

CSL Behring is looking for academic collaborators active in the following areas:

* AUTOIMMUNITY: Research in B cell and plasma cell depletion programs with a focus on

  autoantibody, complement, and T cell-mediated diseases

* RESPIRATORY: Novel drug candidates and targets for progressive fibrosing interstitial lung

  diseases and acute respiratory distress syndrome

* CARDIOVASCULAR: Novel drug candidates and targets with a particular focus on rare

  cardiovascular diseases



Free Registration for the Fall 2020 NIH Virtual Seminar on Program Funding and Grants Administration!

The NIH is bringing the Fall 2020 NIH Virtual Seminar on Program Funding and Grants Administration direct to your computer…

free of charge, Tuesday, October 27 – Friday, October 30!

This event is designed to demystify the NIH grant application and review process! Register today at and be sure to check out all the networking opportunities taking place during the seminar.

The seminar will include:

·                     Four days of sessions

·                     Three tracks

·                     Live chat opportunities

·                     Downloadable resources

·                     Free registration

Keep tabs on the latest registration and agenda updates on the seminar site:




The EHSO News Flash has good information for laboratories with regard to COVID-19, see:



NIH: How Do I Submit Post-Submission Materials for My Application?

Post-submission materials are those submitted after submission of the grant application but prior to initial peer review. 

They are not intended to correct oversights or errors discovered after submission of the application, but rather allow 

applicants the opportunity to respond to unforeseen events. Our policy on post-submission materials outlines allowable 

materials and how to submit them. The steps to submit these materials are summarized here.





OITE will be offering a series of webinars and small group discussions focused on helping graduate students and 

postdoctoral fellows in the sciences develop the resilience needed to thrive in high-knowledge environments. This 

material is helpful for trainees just starting out, those contemplating their next educational move and who are mentoring 

others. Groups will be organized by educational level so trainees can talk with others experiencing similar educational, 

work and life stressors.  For additional information see attached document.  



Patents 101

First Do No Harm - How To Write and Speak about Your Invention Without Losing U.S. or Foreign Patent Rights 

The presenter is Chris Corbett, Director of Intellectual Property in the Office of Technology Commercialization. Learn:

·                     What is a patent?

·                     How/why does a public disclosure affect patentability?

·                     Types of public disclosures

·                     How to publish without hurting your patent rights

·                     Key milestones of the patent process

Wednesday, September 30 at noon.

Join Zoom Meeting

Meeting ID: 998 5225 8950

Password: 4*Jj=DEE



Oklahoma Covid-19 Working Group

Information on research activities in Oklahoma that address the Covid-19 pandemic has been added to the  OCTSI Website 

( A list of investigators in the working group and their planned or ongoing 

projects are described. A list of funded Covid-19 Seed Projects at OUHSC and OU Norman is also included. To be added to 

the Oklahoma Covid-19 Working Group or to have your information updated, please contact: Mark L. Lang PhD, Presbyterian 

Health Foundation Presidential Professor, Department of Microbiology and Immunology, OUHSC ( ).



Up to date information on allowable OUHSC research activity in response to COVID-19 can be found at:



OUHSC Funding Requests related to COVID-19 – when submitting an item in the OUHSC SoonerTrack system related

to COVID-19 please include “COVID-19” in the title so that we are able to search on it later.





Policy for Charging Personal Protective Equipment to NIH Grants and Cooperative Agreements as Direct Costs 


Reminder: NIH Natural Disaster Policy Hurricane Laura (NOT-OD-20-172)

Pre-Application Webinar for RFA-CA-20-040, Aging, Cancer-Initiating Cells, and Cancer Development (U01 Clinical Trial Not 

Allowed) (NOT-CA-20-105)

NIMHD Loan Repayment Program Technical Assistance Webinar (NOT-MD-20-029)

Reissue of Parent Research Supplements to Promote Diversity in Health-Related Research FOA in October 2020 


Notice of Limited Availability of Research Non-human Primates (NOT-OD-20-173)

Updated Information on the Research Projects Component for PAR-20-297 NIOSH Centers of Excellence for Total Worker Health 

(U19) (NOT-OH-20-008)

Notice of Expiration of PAR-18-923 - Characterization of Mycobacterial Induced Immunity in HIV-infected and Uninfected Individuals 

(R21 Clinical Trial Not Allowed) (NOT-AI-20-072)


Notice of Expiration of PAR-19-307 " Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals 

to Inform Innovative Tuberculosis Vaccine Design (R01 Clinical Trial Not Allowed)" (NOT-AI-20-073)

Notice of Extension of the Expiration Date for PAR-18-337 "NCI Mentored Clinical Scientist Research Career Development Award 

to Promote Diversity (K08, No Independent Clinical Trials)"


Notice of Extension of the Expiration Date for PAR-18-364 "NCI Mentored Research Scientist Development Award to Promote 

Diversity (K01 Independent Clinical Trial Not Allowed)"

Notice of Extension of the Expiration Date for PAR-18-365 "NCI Mentored Research Scientist Development Award to Promote 

Diversity (K01 Clinical Trial Required)" (NOT-CA-20-102)


Notice of Extension of the Expiration Date for PAR-18-366 "NCI Transition Career Development Award to Promote Diversity 

(K22 No Independent Clinical Trials)" (NOT-CA-20-103)

Notice of Extension of the Expiration Date for PAR-18-367 "NCI Transition Career Development Award to Promote Diversity 

(K22 Clinical Trial Required)" (NOT-CA-20-104)

Notice of Change to Application Due Date for RFA-DA-21-009, "Interventions to Prevent Electronic Nicotine Delivery Systems 

(ENDS) Use Among Adolescents (R01 - Clinical Trial Optional)"

NOTICE of Eligibility Change for PAR-18-901: Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: 

Fogarty International Research Training Award (NCD-LIFESPAN) (D43)

Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: Non-addictive Analgesic Therapeutics 

Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) (NOT-NS-20-106)

Notice of Special Interest: Alzheimer’s-focused administrative supplements for NIH grants that are not focused on Alzheimer’s 

disease (NOT-AG-20-034)

Notice of Special Interest (NOSI): Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals

to Inform Innovative Tuberculosis Vaccine Design (NOT-AI-20-071)


Notice of Special Interest (NOSI): Training Modules for Creating Safe, Inclusive, and Supportive Research Environments 


Notice of Special Interest: Innovative Technologies to Improve Assessments, Interventions, and Outcomes for Individuals with 

Intellectual and Developmental Disabilities (R43/R44)


Notice of Special Interest (NOSI): Palliative Care in Heart, Lung, Blood, and Sleep Diseases

Notice of Special Interest (NOSI): Research in the Emergency Setting (NOT-NS-20-005)


Notice of Special Interest: Administrative Supplement for the NINDS Research Education Program for Residents and Fellows 

in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (Admin Supp) (NOT-NS-20-038)



Please Note:  When only one application is allowed per Institution according to the sponsor

instructions, a one-page letter of intent summarizing the proposed project should be submitted

to the Vice President for Research at least two months prior to the application deadline (unless

otherwise noted).  The letters of intent will be reviewed and a single application will be chosen  

for submission from the University.




Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness

(ALACRITY) Research Centers (P50 Clinical Trial Optional) (PAR-20-293)
Deadline May 17, 2021 and May 17, 2022


Modules for Enhancing Biomedical Research Workforce Training (R25 Clinical Trial Not Allowed)
(PAR-20-296) - Deadline June 18, 2021 and June 20, 2022


Development of the Fetal Immune System (R01 Clinical Trial Not Allowed) (PAR-20-298)
Eunice Kennedy Shriver National Institute of Child Health and Human Development 
Deadline April 7, 2021 and December 7, 2021


Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional) (PAR-20-299)

Deadline December 10, 2020 and April 9, 2021


Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional) (PAR-20-300)

Deadline December 10, 2020 and April 9, 2021


Limited Competition for the Continuation of the Urinary Stone Disease Research Network (USDRN) Clinical Centers

(U01 Clinical Trial Required) (RFA-DK-20-506) - Deadline February 9, 2021


Limited Competition for the Continuation of the Urinary Stone Disease Research Network (USDRN) Scientific Data Research Center

(U24 Clinical Trial Required) (RFA-DK-20-507) - Deadline February 9, 2021


NIEHS SBIR Phase IIB Validation of Sensors for Improved Environmental Exposure Assessment (R44 Clinical Trial Not Allowed)

(RFA-ES-20-016) - Deadline December 4, 2020




American Diabetes Association – Cardiovascular-Metabolic Fellowship Awards

Deadline October 26, 2020